Asmus Vogel
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Asmus Vogel has a total of 154 co-authors. Here are the top co-authors by number of shared publications:
Gunhild Waldemar
Danish Dementia Research Centre, Department of Neurology Copenhagen University Hospital, Rigshospitalet Copenhagen Denmark
19 shared publications- Steen Gregers Hasselbalch
Danish Dementia Research Centre, Department of Neurology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark
9 shared publications - Frans Boch Waldorff
Section of General Practice, Department of Public Health, University of Copenhagen, Copenhagen, Denmark
6 shared publications - Kristian Steen Frederiksen
Danish Dementia Research Centre, Department of Neurology, Copenhagen University Hospital-Rigshospitalet, Copenhagen, Denmark; Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark
6 shared publications - Rebecca K. Hendel
Danish Dementia Research Centre, Department of Neurology, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark
6 shared publications Anders Gade
Department of Psychology, University of Copenhagen
5 shared publications
Latest Publications
- 4 October 2026
- Published by Taylor & Francis in Applied Neuropsychology: Adult
- p. 1-11
Color Trails test performance in a culturally diverse White sample: applicability of manual norms for Europeans
The Color Trails Test (CTT) was developed as a culture-fair analog of the Trail Making Test (TMT) for the assessment of visual attention, mental flexibility, visual scanning, and motor speed (D’Eli...
- 4 October 2026
- Published by Taylor & Francis in Applied Neuropsychology: Adult
- p. 1-11
Color Trails test performance in a culturally diverse White sample: applicability of manual norms for Europeans
The Color Trails Test (CTT) was developed as a culture-fair analog of the Trail Making Test (TMT) for the assessment of visual attention, mental flexibility, visual scanning, and motor speed (D’Eli...
- Open Access
- 13 May 2026
- Published by Wiley in Scandinavian Journal of Psychology
- Vol. 67 (5) , 1351-1358
Subjective Cognitive Complaints and Hearing Loss in Older Adults—A Cross‐Sectional Study on the Possible Association
An association between hearing loss and cognitive decline has been found in many epidemiological and clinical studies but few studies have investigated if objectively measured hearing loss is associated with subjective cognitive complaints. Both factors increase with age and are linked to future cognitive decline/dementia. The aim was to investigate if the degree of subjective cognitive complaints was significantly associated with the level of hearing in older adults. Moreover, to what extent this relationship would persist if factors such as age, cognitive dysfunction, and depression were accounted for. Cognitive Function Instrument (CFI) and Cognitive Change Index (CCI) were applied in 60 community‐dwelling adults and 83 audiology clinic patients. Participants were 55 years or older and were assessed with Pure Tone Audiometry (PTA), Geriatric Depression Scale, the Logical Memory Test, and Symbol Digit Modalities Test. Persons with moderate‐to‐severe hearing loss had significantly higher scores than persons with normal hearing on CFI and CCI. Significant group differences were also found for tests of episodic memory and processing speed. PTA results were significantly correlated to both CCI (rho = 0.21) and CFI (rho = 0.25). Regression‐based models did not show an independent and significant effect of hearing on subjective cognitive complaints when age, sex, depressive symptoms, and cognitive test scores were also included in the analysis. In conclusion, subjective cognitive complaints increase with decreased hearing (as measured by tone detection) but the association seems to be moderated by other factors such as depressive symptoms and neuropsychological test performances.
- 13 May 2026
- Published by Wiley in Scandinavian Journal of Psychology
- Vol. 67 (5) , 1351-1358
Open AccessSubjective Cognitive Complaints and Hearing Loss in Older Adults—A Cross‐Sectional Study on the Possible Association
An association between hearing loss and cognitive decline has been found in many epidemiological and clinical studies but few studies have investigated if objectively measured hearing loss is associated with subjective cognitive complaints. Both factors increase with age and are linked to future cognitive decline/dementia. The aim was to investigate if the degree of subjective cognitive complaints was significantly associated with the level of hearing in older adults. Moreover, to what extent this relationship would persist if factors such as age, cognitive dysfunction, and depression were accounted for. Cognitive Function Instrument (CFI) and Cognitive Change Index (CCI) were applied in 60 community‐dwelling adults and 83 audiology clinic patients. Participants were 55 years or older and were assessed with Pure Tone Audiometry (PTA), Geriatric Depression Scale, the Logical Memory Test, and Symbol Digit Modalities Test. Persons with moderate‐to‐severe hearing loss had significantly higher scores than persons with normal hearing on CFI and CCI. Significant group differences were also found for tests of episodic memory and processing speed. PTA results were significantly correlated to both CCI (rho = 0.21) and CFI (rho = 0.25). Regression‐based models did not show an independent and significant effect of hearing on subjective cognitive complaints when age, sex, depressive symptoms, and cognitive test scores were also included in the analysis. In conclusion, subjective cognitive complaints increase with decreased hearing (as measured by tone detection) but the association seems to be moderated by other factors such as depressive symptoms and neuropsychological test performances.
- Open Access
- 21 April 2026
- Published by Springer Nature in Journal of Neurology
- Vol. 273 (5) , 285
Longitudinal trajectories of apathy in Huntington’s disease: a 6-year follow-up study
Objective: Apathy is a common and debilitating neuropsychiatric symptom in Huntington’s disease (HD), yet its long-term trajectory remains poorly characterized. This study examined changes in apathy in HD gene expansion carriers (HDGECs) over 6 years, using a multidimensional measure, and investigated associations with cognition, motor symptoms and depression. Methods: Eighty-two HDGECs (premanifest and manifest) completed assessments at Time 0 and Time 1 with a mean follow-up interval of 6 years. Apathy was measured using the Lille Apathy Rating Scale (LARS) and the Problem Behaviors Assessment–short (PBA-s). Depressive symptoms were assessed with the Hamilton Depression Rating Scale, while social cognition and executive functioning were measured using the Emotion Hexagon and Symbol Digit Modalities Test. Within-person changes were examined using paired statistical tests and associations with clinical variables were evaluated using correlation analyses. Results: Total apathy scores increased significantly over 6 years, with small changes (LARS: 1.38 points; PBA-s: 1.11 points). Premanifest participants showed a selective decline in Action Initiation, whereas manifest participants exhibited a broader worsening of total apathy. Individual trajectories were variable, with both worsening and improvement observed. An increase in depressive symptoms was significantly correlated with changes in apathy but accounted for little variance. Conclusion: Apathy in HD shows a small but significant increase over 6 years, characterized by marked heterogeneity and changes in Action Initiation. The limited association with depression and cognition highlights apathy as an independent neuropsychiatric feature. These findings underscore the heterogeneous nature of apathy progression and the value of multidimensional assessment in longitudinal studies.
- 21 April 2026
- Published by Springer Nature in Journal of Neurology
- Vol. 273 (5) , 285
Open AccessLongitudinal trajectories of apathy in Huntington’s disease: a 6-year follow-up study
Objective: Apathy is a common and debilitating neuropsychiatric symptom in Huntington’s disease (HD), yet its long-term trajectory remains poorly characterized. This study examined changes in apathy in HD gene expansion carriers (HDGECs) over 6 years, using a multidimensional measure, and investigated associations with cognition, motor symptoms and depression. Methods: Eighty-two HDGECs (premanifest and manifest) completed assessments at Time 0 and Time 1 with a mean follow-up interval of 6 years. Apathy was measured using the Lille Apathy Rating Scale (LARS) and the Problem Behaviors Assessment–short (PBA-s). Depressive symptoms were assessed with the Hamilton Depression Rating Scale, while social cognition and executive functioning were measured using the Emotion Hexagon and Symbol Digit Modalities Test. Within-person changes were examined using paired statistical tests and associations with clinical variables were evaluated using correlation analyses. Results: Total apathy scores increased significantly over 6 years, with small changes (LARS: 1.38 points; PBA-s: 1.11 points). Premanifest participants showed a selective decline in Action Initiation, whereas manifest participants exhibited a broader worsening of total apathy. Individual trajectories were variable, with both worsening and improvement observed. An increase in depressive symptoms was significantly correlated with changes in apathy but accounted for little variance. Conclusion: Apathy in HD shows a small but significant increase over 6 years, characterized by marked heterogeneity and changes in Action Initiation. The limited association with depression and cognition highlights apathy as an independent neuropsychiatric feature. These findings underscore the heterogeneous nature of apathy progression and the value of multidimensional assessment in longitudinal studies.
- 13 March 2026
- Published by SAGE Publications in Journal of Alzheimer’s Disease
- Vol. 110 (4) , 1713-1722
A comparison of hearing abilities in memory clinic patients with mild cognitive impairment and cognitively intact older adults
Background: Evidence on the prevalence and nature of hearing impairments among patients with Alzheimer's disease and other types of dementia is limited and inconsistent. Objective: The objective of this study was to compare the proportion of individuals with hearing loss and the severity of hearing impairments in peripheral hearing and speech perception in noise of patients with mild cognitive impairment (MCI) and cognitively intact older adults. Methods: Participants included 40 patients with MCI recruited from a memory clinic and 60 community-dwelling cognitively intact older adults (Clinical Dementia Rating Score of 0 and Mini-Mental State Examination ≥ 26). All participants were assessed with pure-tone audiometry and a speech-in-noise test, and with cognitive tests tapping memory, processing speed, executive functions, attention, and language. Results: No significant difference was found in the proportion of individuals with peripheral hearing loss among patients with MCI and cognitively intact older adults (77.5% and 60%, respectively). Speech-in-noise did not differ between the groups either, not even when accounting for aided hearing in those participants that wore hearing aids in their daily life. About one third of patients with MCI did not perceive hearing problems, despite having objectively measured hearing loss. However, this proportion did not differ significantly from the group of cognitively intact older adults. Conclusions: Despite differences in cognitive status, this study did not show significant differences between the groups on measures of peripheral hearing, speech-in-noise, and subjective complaints of hearing when comparing memory clinic patients with cognitively intact older adults.
- 13 March 2026
- Published by SAGE Publications in Journal of Alzheimer’s Disease
- Vol. 110 (4) , 1713-1722
A comparison of hearing abilities in memory clinic patients with mild cognitive impairment and cognitively intact older adults
Background: Evidence on the prevalence and nature of hearing impairments among patients with Alzheimer's disease and other types of dementia is limited and inconsistent. Objective: The objective of this study was to compare the proportion of individuals with hearing loss and the severity of hearing impairments in peripheral hearing and speech perception in noise of patients with mild cognitive impairment (MCI) and cognitively intact older adults. Methods: Participants included 40 patients with MCI recruited from a memory clinic and 60 community-dwelling cognitively intact older adults (Clinical Dementia Rating Score of 0 and Mini-Mental State Examination ≥ 26). All participants were assessed with pure-tone audiometry and a speech-in-noise test, and with cognitive tests tapping memory, processing speed, executive functions, attention, and language. Results: No significant difference was found in the proportion of individuals with peripheral hearing loss among patients with MCI and cognitively intact older adults (77.5% and 60%, respectively). Speech-in-noise did not differ between the groups either, not even when accounting for aided hearing in those participants that wore hearing aids in their daily life. About one third of patients with MCI did not perceive hearing problems, despite having objectively measured hearing loss. However, this proportion did not differ significantly from the group of cognitively intact older adults. Conclusions: Despite differences in cognitive status, this study did not show significant differences between the groups on measures of peripheral hearing, speech-in-noise, and subjective complaints of hearing when comparing memory clinic patients with cognitively intact older adults.
- Open Access
- 1 January 2026
- Published by SAGE Publications in Trends in Hearing
- Vol. 30
Association Between Age-Related Sensory and Metabolic Hearing Loss and Cognitive Performance
The underlying mechanisms linking age-related hearing loss (HL), and cognitive dysfunction are not well-understood. Traditionally, age-related HL was primarily related to damage of hair cells (i.e., the sensory component of HL) however, growing evidence suggests that the endocochlear potential (i.e., the metabolic component of HL) may also play a role. In this study, we investigated the relationship between the sensory and metabolic components of HL and cognitive dysfunction in 100 older adults. Forty participants were patients with mild cognitive impairment recruited during visits to the Memory Clinic at the Danish Dementia Research Centre, while 60 participants were recruited from the general public. All participants were assessed with pure-tone audiometry and a comprehensive cognitive test battery including but not limited to tests examining, episodic memory, processing speed, and executive functions. The sensory and metabolic components of the HL were estimated based on the age-related HL components model. Metabolic HL was strongly correlated with performance on tests of processing speed, moderately correlated with performances on tests of executive function, but not significantly correlated with episodic memory performance. On the other hand, sensory HL was not significantly correlated with any of the cognitive tests. When correcting for age, the correlation between metabolic HL and processing speed remained significant. Thus, participants with lower processing speed were significantly more likely to have a larger metabolic HL. These data could lend support to the idea that shared vascular pathophysiological mechanisms are a key link between age-related HL and cognitive decline.
- 1 January 2026
- Published by SAGE Publications in Trends in Hearing
- Vol. 30
Open AccessAssociation Between Age-Related Sensory and Metabolic Hearing Loss and Cognitive Performance
The underlying mechanisms linking age-related hearing loss (HL), and cognitive dysfunction are not well-understood. Traditionally, age-related HL was primarily related to damage of hair cells (i.e., the sensory component of HL) however, growing evidence suggests that the endocochlear potential (i.e., the metabolic component of HL) may also play a role. In this study, we investigated the relationship between the sensory and metabolic components of HL and cognitive dysfunction in 100 older adults. Forty participants were patients with mild cognitive impairment recruited during visits to the Memory Clinic at the Danish Dementia Research Centre, while 60 participants were recruited from the general public. All participants were assessed with pure-tone audiometry and a comprehensive cognitive test battery including but not limited to tests examining, episodic memory, processing speed, and executive functions. The sensory and metabolic components of the HL were estimated based on the age-related HL components model. Metabolic HL was strongly correlated with performance on tests of processing speed, moderately correlated with performances on tests of executive function, but not significantly correlated with episodic memory performance. On the other hand, sensory HL was not significantly correlated with any of the cognitive tests. When correcting for age, the correlation between metabolic HL and processing speed remained significant. Thus, participants with lower processing speed were significantly more likely to have a larger metabolic HL. These data could lend support to the idea that shared vascular pathophysiological mechanisms are a key link between age-related HL and cognitive decline.
- 8 August 2025
- Published by SAGE Publications in Journal of Alzheimer’s Disease
The Danish Dementia Research Centre: Integrating patient care, clinical research, and national educational services
The Copenhagen Memory Clinic was established in 1995 and since 2007 a new national center for research and education was established, together forming the Danish Dementia Research Centre (DDRC). Our research and innovation programs have continuously been informed by clinical experience and inspired by the needs of our patients. The link between patient care, research, and education forming together a comprehensive dementia center is therefore of crucial importance. In this review, we present an overview of the clinical program at the Copenhagen Memory Clinic, currently receiving 2.000 new referrals per year. We also present the Copenhagen Memory Clinic Cohort and the associated biobank, as well as clinical, translational and epidemiological research programs performed at DDRC during the past 30 years. Funded in part by the Danish Ministry of Health, our national outreach, professional networks and educational programs are also outlined. From its inception and onwards the primary focus of the DDRC has been with the patients, aiming to continuously improve our clinical service based on research and innovation and to improve the quality of care nationwide. We welcome requests for collaboration on research, innovation and education from international colleagues and research centers.
- 8 August 2025
- Published by SAGE Publications in Journal of Alzheimer’s Disease
The Danish Dementia Research Centre: Integrating patient care, clinical research, and national educational services
The Copenhagen Memory Clinic was established in 1995 and since 2007 a new national center for research and education was established, together forming the Danish Dementia Research Centre (DDRC). Our research and innovation programs have continuously been informed by clinical experience and inspired by the needs of our patients. The link between patient care, research, and education forming together a comprehensive dementia center is therefore of crucial importance. In this review, we present an overview of the clinical program at the Copenhagen Memory Clinic, currently receiving 2.000 new referrals per year. We also present the Copenhagen Memory Clinic Cohort and the associated biobank, as well as clinical, translational and epidemiological research programs performed at DDRC during the past 30 years. Funded in part by the Danish Ministry of Health, our national outreach, professional networks and educational programs are also outlined. From its inception and onwards the primary focus of the DDRC has been with the patients, aiming to continuously improve our clinical service based on research and innovation and to improve the quality of care nationwide. We welcome requests for collaboration on research, innovation and education from international colleagues and research centers.
- 6 May 2025
- Published by SAGE Publications in Journal of Alzheimer’s Disease
- Vol. 106 (1) , 111-119
Isolated elevation of 181p-tau in the cerebrospinal fluid is associated with distinct clinical features: Findings from a Danish memory clinic cohort
Background: Deposition of amyloid-β and tau are key pathological events in Alzheimer's disease and may be assessed by cerebrospinal fluid (CSF) biomarkers. It remains uncertain whether patients who display abnormal phosphorylated tau in isolation differ from patients with other biomarker profiles. Objective: The primary objective was to investigate differences in demographics, comorbidities, and cognitive performance in amyloid-β negative phosphorylated tau positive patients. Further, the aim was also to investigate the relationship between cognitive function and phosphorylated tau level. Methods: A total of 1049 consecutive patients from the Copenhagen Memory Clinic Cohort from 2018 to August 2022 were included and divided into four groups based on the CSF biomarkers amyloid-β 42 (A) and phosphorylated tau (T). Data on co-morbidities, abuse, and neuropsychological tests were recorded, and retrospective data analyses were performed across all groups. Results: A total of 2.8% participants had an A–T+ biomarker profile and were younger (Mean: 65.1 years, SD: 14.2), comprised of more men (65.5%) than the A + T– group and exhibited both more psychiatric illness (p = 0.027) and alcohol and/or drug abuse (p = 0.004) than the A + T+ group. The A–T+ group performed better on both Addenbrooke's Cognitive Examination (p = 0.002) and Mini-Mental State Examination (p = 0.001) as well as immediate (p = 0.026) and delayed recall (p = 0.009) compared to the A + T+ group but showed no difference compared to the A–T– group on all cognitive scores. Further, higher p-tau levels were associated with worse cognitive performance although effects were small. Conclusions: The findings indicate that patients with the A–T+ biomarker profile have different clinical characteristic that may indicate a non-neurodegenerative background.
- 6 May 2025
- Published by SAGE Publications in Journal of Alzheimer’s Disease
- Vol. 106 (1) , 111-119
Isolated elevation of 181p-tau in the cerebrospinal fluid is associated with distinct clinical features: Findings from a Danish memory clinic cohort
Background: Deposition of amyloid-β and tau are key pathological events in Alzheimer's disease and may be assessed by cerebrospinal fluid (CSF) biomarkers. It remains uncertain whether patients who display abnormal phosphorylated tau in isolation differ from patients with other biomarker profiles. Objective: The primary objective was to investigate differences in demographics, comorbidities, and cognitive performance in amyloid-β negative phosphorylated tau positive patients. Further, the aim was also to investigate the relationship between cognitive function and phosphorylated tau level. Methods: A total of 1049 consecutive patients from the Copenhagen Memory Clinic Cohort from 2018 to August 2022 were included and divided into four groups based on the CSF biomarkers amyloid-β 42 (A) and phosphorylated tau (T). Data on co-morbidities, abuse, and neuropsychological tests were recorded, and retrospective data analyses were performed across all groups. Results: A total of 2.8% participants had an A–T+ biomarker profile and were younger (Mean: 65.1 years, SD: 14.2), comprised of more men (65.5%) than the A + T– group and exhibited both more psychiatric illness (p = 0.027) and alcohol and/or drug abuse (p = 0.004) than the A + T+ group. The A–T+ group performed better on both Addenbrooke's Cognitive Examination (p = 0.002) and Mini-Mental State Examination (p = 0.001) as well as immediate (p = 0.026) and delayed recall (p = 0.009) compared to the A + T+ group but showed no difference compared to the A–T– group on all cognitive scores. Further, higher p-tau levels were associated with worse cognitive performance although effects were small. Conclusions: The findings indicate that patients with the A–T+ biomarker profile have different clinical characteristic that may indicate a non-neurodegenerative background.
- Open Access
- 13 October 2024
- Published by Wiley in Scandinavian Journal of Psychology
- Vol. 66 (2) , 175-182
Self‐Concept in Mild Cognitive Impairment and Mild Dementia due to Alzheimer's Disease Is Affected on Tests of Self‐Generated Statements
Several studies show that Alzheimer's disease (AD) and other neurocognitive disorders have a negative impact on the self and identity formation. Most studies have included persons with mild to moderate dementia, but how AD patients in the earliest phases retrieve information about themselves has only been studied scarcely. The aim of this study was to investigate if persons with mild cognitive impairment (MCI) and mild AD would generate fewer self‐related statements than healthy controls. From a memory clinic, we included 17 aMCI patients, 17 patients with mild dementia (AD; MMSE ≥ 24), and 30 healthy controls. Three Events Test and Twenty Statements Test (TST) were applied to all participants. The persons with mild dementia gave significantly fewer statements compared to the controls (p < 0.001) and the aMCI patients (p < 0.01) on TST. Fewer statements were also produced by the aMCI patients compared to the control participants (p < 0.05). Persons from both patient groups produced significantly fewer contextual details compared to the controls on the Three Events Tests. There were significant associations to lexical fluency for both the TST and Three Events Test, but only a limited amount of variance was explained, and the results cannot be explained solely by a fluency effect. The results from this study are in accordance with findings from previous studies demonstrating that mild AD leads to a decline in both autobiographical memories and a diminished sense of self. Further, this study shows that changes in self‐concept may occur even in the earliest clinical stages of AD.
- 13 October 2024
- Published by Wiley in Scandinavian Journal of Psychology
- Vol. 66 (2) , 175-182
Open AccessSelf‐Concept in Mild Cognitive Impairment and Mild Dementia due to Alzheimer's Disease Is Affected on Tests of Self‐Generated Statements
Several studies show that Alzheimer's disease (AD) and other neurocognitive disorders have a negative impact on the self and identity formation. Most studies have included persons with mild to moderate dementia, but how AD patients in the earliest phases retrieve information about themselves has only been studied scarcely. The aim of this study was to investigate if persons with mild cognitive impairment (MCI) and mild AD would generate fewer self‐related statements than healthy controls. From a memory clinic, we included 17 aMCI patients, 17 patients with mild dementia (AD; MMSE ≥ 24), and 30 healthy controls. Three Events Test and Twenty Statements Test (TST) were applied to all participants. The persons with mild dementia gave significantly fewer statements compared to the controls (p < 0.001) and the aMCI patients (p < 0.01) on TST. Fewer statements were also produced by the aMCI patients compared to the control participants (p < 0.05). Persons from both patient groups produced significantly fewer contextual details compared to the controls on the Three Events Tests. There were significant associations to lexical fluency for both the TST and Three Events Test, but only a limited amount of variance was explained, and the results cannot be explained solely by a fluency effect. The results from this study are in accordance with findings from previous studies demonstrating that mild AD leads to a decline in both autobiographical memories and a diminished sense of self. Further, this study shows that changes in self‐concept may occur even in the earliest clinical stages of AD.
- Open Access
- 25 December 2023
- Published by Wiley in Alzheimer's & Dementia
- Vol. 19 (S16)
Clinical Validation and Correlates of the Cingulate Island Sign Visual Rating Scale for the Diagnosis of Dementia with Lewy Bodies
Background: The cingulate island sign (CIS) is a metabolic pattern on [18F]fluorodeoxyglucose ([18F]FDG) positron emission tomography (PET) associated with dementia with Lewy bodies (DLB). The aim of this study was to validate the visual CIS rating scale (CISRs) for the diagnosis of DLB and to explore the clinical correlates.Method: This single‐center, retrospective study included 166 consecutive patients with DLB and 161 patients with Alzheimer’s disease (AD). The CIS on [18F]FDG‐PET scans was rated using the CISRs (0‐4) independently by three readers blinded to other patient data.Result: The optimal cut‐off to differentiate DLB from AD was a CISRs score ≥ 1 (sensitivity = 66%, specificity = 84%) whereas a CISRs score ≥ 2 (sensitivity = 58%, specificity = 92%) was optimal to differentiate amyloid positive DLB (n = 43 (82.7%)) and AD. To identify DLB with abnormal (n = 53 (72.6%)) versus normal (n = 20 (27.4%)) dopamine transporter imaging (DaT), a CISRs cut‐off of 4 had a specificity of 95% for abnormal DaT. DLB patients with a CISRs score of 4 performed significantly better in tests of free verbal recall and picture based cued recall, but worse in test of processing speed compared with DLB with a CISRs score of 0.Conclusion: This study confirms the CISRs as a valid marker for the diagnosis of DLB with a high specificity and a lower, but acceptable, sensitivity. Concomitant AD pathology does not influence diagnostic accuracy of the CISRs. In DLB patients, presence of CIS is associated with relative preserved memory function and impaired processing speed.
- 25 December 2023
- Published by Wiley in Alzheimer's & Dementia
- Vol. 19 (S16)
Open AccessClinical Validation and Correlates of the Cingulate Island Sign Visual Rating Scale for the Diagnosis of Dementia with Lewy Bodies
Background: The cingulate island sign (CIS) is a metabolic pattern on [18F]fluorodeoxyglucose ([18F]FDG) positron emission tomography (PET) associated with dementia with Lewy bodies (DLB). The aim of this study was to validate the visual CIS rating scale (CISRs) for the diagnosis of DLB and to explore the clinical correlates.Method: This single‐center, retrospective study included 166 consecutive patients with DLB and 161 patients with Alzheimer’s disease (AD). The CIS on [18F]FDG‐PET scans was rated using the CISRs (0‐4) independently by three readers blinded to other patient data.Result: The optimal cut‐off to differentiate DLB from AD was a CISRs score ≥ 1 (sensitivity = 66%, specificity = 84%) whereas a CISRs score ≥ 2 (sensitivity = 58%, specificity = 92%) was optimal to differentiate amyloid positive DLB (n = 43 (82.7%)) and AD. To identify DLB with abnormal (n = 53 (72.6%)) versus normal (n = 20 (27.4%)) dopamine transporter imaging (DaT), a CISRs cut‐off of 4 had a specificity of 95% for abnormal DaT. DLB patients with a CISRs score of 4 performed significantly better in tests of free verbal recall and picture based cued recall, but worse in test of processing speed compared with DLB with a CISRs score of 0.Conclusion: This study confirms the CISRs as a valid marker for the diagnosis of DLB with a high specificity and a lower, but acceptable, sensitivity. Concomitant AD pathology does not influence diagnostic accuracy of the CISRs. In DLB patients, presence of CIS is associated with relative preserved memory function and impaired processing speed.
- Open Access
- 25 December 2023
- Published by Wiley in Alzheimer's & Dementia
- Vol. 19 (S16)
The Cingulate Island Sign in a Mixed Memory Population: Prevalence and Diagnostic Accuracy
Background: Visual rating of the cingulate island sign (CIS) on [18F]fluorodeoxyglucose ([18F]FDG) position emission tomography (PET) has a high specificity for dementia with Lewy bodies (DLB) in selected populations such as DLB versus Alzheimer’s disease (AD). This study aims to uncover the prevalence of CIS in an unselected memory clinic population, diagnostic accuracy to detect DLB, and the relationship between CIS and disease severity.Method: We assessed the CIS on [18F]FDG‐PET with the visual CIS rating scale (CISRs) in 1000 consecutive patients with a syndrome diagnosis of dementia or mild cognitive impairment (MCI) with no restrictions in terms of etiological diagnosis.Result: Possible (CISRs score 1‐2) or definite CIS (CISRs score 3‐4) was found in 24.3% of the cohort and 7.8% had definite CIS. The prevalence of definite or possible CIS was highest in DLB (n = 57 (74.0%)) followed by AD/AD + vascular dementia (AD/AD + VaD) (n = 158, (26.0%)) and other non‐neurodegenerative diseases (n = 6 (9.5%)). The prevalence of CIS across disease severities showed no statistically significant difference (p = 0.23). To differentiate DLB from non‐DLB with MCI or mild dementia the cut‐off which yielded the highest balanced accuracy was at CISRs score ≥ 1 (balanced accuracy = 77.1%) and in moderate or severe dementia a cut‐off at CISRs score ≥ 2 yielded the highest balanced accuracy (80.6%). The positive predictive value of definite CIS for DLB was 48.5% in MCI or mild dementia and 31.3% in moderate or severe dementia.Conclusion: CIS on [18F]FDG‐PET is most prevalent in DLB followed by AD/AD + VaD. The prevalence of CIS across disease severities showed no significant difference. CISRs is useful in differentiating DLB from a variety of other diagnosis in a mixed memory cohort, and the diagnostic accuracy was comparable at early and late stages of dementia.
- 25 December 2023
- Published by Wiley in Alzheimer's & Dementia
- Vol. 19 (S16)
Open AccessThe Cingulate Island Sign in a Mixed Memory Population: Prevalence and Diagnostic Accuracy
Background: Visual rating of the cingulate island sign (CIS) on [18F]fluorodeoxyglucose ([18F]FDG) position emission tomography (PET) has a high specificity for dementia with Lewy bodies (DLB) in selected populations such as DLB versus Alzheimer’s disease (AD). This study aims to uncover the prevalence of CIS in an unselected memory clinic population, diagnostic accuracy to detect DLB, and the relationship between CIS and disease severity.Method: We assessed the CIS on [18F]FDG‐PET with the visual CIS rating scale (CISRs) in 1000 consecutive patients with a syndrome diagnosis of dementia or mild cognitive impairment (MCI) with no restrictions in terms of etiological diagnosis.Result: Possible (CISRs score 1‐2) or definite CIS (CISRs score 3‐4) was found in 24.3% of the cohort and 7.8% had definite CIS. The prevalence of definite or possible CIS was highest in DLB (n = 57 (74.0%)) followed by AD/AD + vascular dementia (AD/AD + VaD) (n = 158, (26.0%)) and other non‐neurodegenerative diseases (n = 6 (9.5%)). The prevalence of CIS across disease severities showed no statistically significant difference (p = 0.23). To differentiate DLB from non‐DLB with MCI or mild dementia the cut‐off which yielded the highest balanced accuracy was at CISRs score ≥ 1 (balanced accuracy = 77.1%) and in moderate or severe dementia a cut‐off at CISRs score ≥ 2 yielded the highest balanced accuracy (80.6%). The positive predictive value of definite CIS for DLB was 48.5% in MCI or mild dementia and 31.3% in moderate or severe dementia.Conclusion: CIS on [18F]FDG‐PET is most prevalent in DLB followed by AD/AD + VaD. The prevalence of CIS across disease severities showed no significant difference. CISRs is useful in differentiating DLB from a variety of other diagnosis in a mixed memory cohort, and the diagnostic accuracy was comparable at early and late stages of dementia.